Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Jacksonville/Florida, FL
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Jacksonville/Florida, FL
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Miami, FL
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Ocoee/Florida, FL
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Ocoee/Florida, FL
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Saint Cloud, FL
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Saint Cloud, FL
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Atlanta, GA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Bloomingdale, IL
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Bloomingdale, IL
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Chicago, IL
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Oak Brook, IL
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Oak Brook, IL
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
South Bend, IN
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
South Bend, IN
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Lafayette, LA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Lafayette, LA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Lake Charles, LA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Oxon Hill, MD
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Boston, MA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Gulfport, MS
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Gulfport, MS
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Jackson, MS
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Kosciusko, MS
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Kosciusko, MS
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Rolling Fork, MS
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Rolling Fork, MS
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Chesterfield, MO
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
St. Louis/Missouri, MO
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
St. Louis/Missouri, MO
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Henderson, NV
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Henderson, NV
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Clifton, NJ
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Clifton, NJ
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Commack, NY
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Commack, NY
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Ithaca, NY
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Ithaca, NY
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
New York, NY
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Asheboro/North Carolina, NC
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Asheboro/North Carolina, NC
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Canal Fulton, OH
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Canal Fulton, OH
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Bensalem/Pennsylvania, PA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Bensalem/Pennsylvania, PA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
West Chester, PA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
West Chester, PA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Manning, SC
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Manning, SC
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Simpsonville, SC
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Athens/Tennessee, TN
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Athens/Tennessee, TN
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Corpus Christi, TX
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Dallas, TX
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Harlingen/Texas, TX
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Harlingen/Texas, TX
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Houston, TX
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Midland, TX
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Midland, TX
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
San Anonio, TX
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
San Anonio, TX
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
San Antonio, TX
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Burke, VA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Burke, VA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Bellevue, WA
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated:  9/26/2017
GSK Investigational Site
mi
from
Langley,
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
Status: Enrolling
Updated: 9/26/2017
GSK Investigational Site
mi
from
Langley,
Click here to add this to my saved trials
Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tekturna (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension
Status: Enrolling
Updated:  9/27/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tekturna (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension
Status: Enrolling
Updated: 9/27/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting
Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting
Status: Enrolling
Updated:  9/27/2017
Riverside County Regional Medical Center
mi
from
Moreno Valley, CA
Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting
Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting
Status: Enrolling
Updated: 9/27/2017
Riverside County Regional Medical Center
mi
from
Moreno Valley, CA
Click here to add this to my saved trials
The VA Diabetes Trial Follow-up Study (VADT-FS)
CSP #465FS - VA Diabetes Trial Long Term Follow-up Study
Status: Enrolling
Updated:  10/2/2017
Phoenix VA Health Care System, Phoenix, AZ
mi
from
Phoenix, AZ
The VA Diabetes Trial Follow-up Study (VADT-FS)
CSP #465FS - VA Diabetes Trial Long Term Follow-up Study
Status: Enrolling
Updated: 10/2/2017
Phoenix VA Health Care System, Phoenix, AZ
mi
from
Phoenix, AZ
Click here to add this to my saved trials
The VA Diabetes Trial Follow-up Study (VADT-FS)
CSP #465FS - VA Diabetes Trial Long Term Follow-up Study
Status: Enrolling
Updated:  10/2/2017
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
The VA Diabetes Trial Follow-up Study (VADT-FS)
CSP #465FS - VA Diabetes Trial Long Term Follow-up Study
Status: Enrolling
Updated: 10/2/2017
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  10/2/2017
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 10/2/2017
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  10/2/2017
Novo Nordisk Investigational Site
mi
from
Neuss,
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 10/2/2017
Novo Nordisk Investigational Site
mi
from
Neuss,
Click here to add this to my saved trials
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Status: Enrolling
Updated:  10/3/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Status: Enrolling
Updated: 10/3/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials